… , 22 letermovir at a dose of 240 mg per day was highly effective in preventing CMV viremia
after engraftment in transplant … of letermovir for CMV prophylaxis after transplantation in CMV-…

… debut of letermovir as standard CMV prophylaxis in … letermovir prophylaxis, and had no
reactivated CMV requiring preemptive antiviral therapy before initiation of letermovir prophylaxis. …

… with letermovir, we show that primary letermovir prophylaxis was efficacious in preventing
CMV infection in CMV … Only 2 (5%) of 39 patients who received primary letermovir prophylaxis …

… in clinically significant CMV infections (CS-CMVi) in clinical trials of CMV-… letermovir
prophylaxis in this population on the incidence and outcomes of refractory or resistant CMV …

… significant CMV reactivation. While letermovir has been approved for prophylactic use in CMV
… The objective of the study was to examine the use of letermovir for prophylaxis from CMV …

… Cytomegalovirus (CMV) infection and disease remain clinically important complications after
allogeneic hematopoietic cell transplantation (… the effects of letermovir prophylaxis on all-…

… -cytomegalovirus (CMV) agent, letermovir (LMV), could reportedly improve the outcomes of
allogeneic hematopoietic cell transplantation … potential to prevent CMV reactivation. Therefore…

… real-world data on the efficacy and safety of letermovir. Here, we describe our single-center
experience using letermovir for CMV prophylaxis among high-risk allogeneic HCT recipients. …

… ) hematopoietic cell transplant (HCT) recipients have a survival disparity compared with CMV-…
We hypothesized that primary letermovir prophylaxis (LET) may abrogate this disparity. We …

… Letermovir primary prophylaxis given for the first 3 months after allogeneic hematopoietic
cell transplantation (HCT) has been shown to reduce clinically significant CMV infection and is …